SVREW vs LFMD vs HIMS vs CELH vs TDOC

For growth investors, Celsius Holdings, Inc.

(CELH) is the stronger pick with 85. 5% revenue growth year-over-year, versus -38. 1% for SaverOne 2014 Ltd (SVREW). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (58. 3x forward), making it the more compelling value choice. Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus Celsius Holdings, Inc. at 137. 0x. On forward P/E, Celsius Holdings, Inc. is actually cheaper at 21. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -97. 1% for SaverOne 2014 Ltd (SVREW). Over 10 years, the gap is even starker: CELH returned +38. 9% versus SVREW's -96. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Celsius Holdings, Inc.

(CELH) is the lower-risk stock at 1. 28β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 94% more volatile than CELH relative to the S&P 500. On balance sheet safety, Celsius Holdings, Inc. (CELH) carries a lower debt/equity ratio of 23% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Celsius Holdings, Inc.

(CELH) is pulling ahead at 85. 5% versus -38. 1% for SaverOne 2014 Ltd (SVREW). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -44. 4% for Celsius Holdings, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -20. 8% for SaverOne 2014 Ltd — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CELH leads at 18. 6% versus -1975. 8% for SVREW. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Celsius Holdings, Inc.

(CELH) trades at 21. 3x forward P/E versus 58. 3x for Hims & Hers Health, Inc. — 37. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LFMD: 89. 3% to $8. 50.

In this comparison, LFMD (1.

5% yield), CELH (0. 5% yield) pay a dividend. SVREW, HIMS, TDOC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Celsius Holdings, Inc.

(CELH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CELH: +38. 9%, TDOC: -38. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVREW (Technology) and LFMD (Healthcare) and HIMS (Healthcare) and CELH (Consumer Defensive) and TDOC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVREW is a small-cap quality compounder stock; LFMD is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; CELH is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock. LFMD pays a dividend while SVREW, HIMS, CELH, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.